appConfigEntityId

bodyType

customContents

entityId

entityUuid

isVideo

articlePageQuery

article

articleSchemaContent

content

hooksArticlePageAdvertisementConfigArticle

hooksArticlePageFloatingButtonConfigArticle

appConfig

filter

json

liveArticle

Julie Zhang

In a landmark development, Neuracle Medical Technology has secured the country’s first-ever approval for an implantable brain-computer interface (BCI) system designed to restore hand motor function in patients with spinal cord injuries, in a regulatory milestone that underscores China’s accelerating push in neurotechnology.
China’s BCI start-ups, seen as potential rivals to Elon Musk’s Neuralink, are gaining momentum as regulatory support and fresh capital fuel growth.
Shares of BCI companies rose on mainland Chinese exchanges on Friday, with Shenzhen-listed Inkon Life Technology surging more than 10 per cent.
The approval awarded to Neuracle, a private firm founded in 2011, marked the first time globally that an invasive BCI could be sold and used on patients as a commercial product, according to China’s National Medical Products Administration.
The company’s founder, Xu Honglai, earned a PhD in biomedical engineering from Tsinghua University.
Last month, Neuracle, which develops and sells scientific research equipment, launched its listing process on the Star Market of the Shanghai Stock Exchange by signing an initial public offering tutoring agreement with Citic Securities.
The newly approved implantable BCI hand motor function system was described by the company as a coin-sized wireless device placed on the brain’s outer surface without penetrating tissue, designed to read patients’ neural signals and translate them into hand movements.

Another BCI start-up, Shanghai-based StairMed Technology, on Friday raised 500 million yuan (US$72.6 million) in a funding round led by Alibaba Group Holding. With this round, StairMed’s total funding in the past year crossed 1.1 billion yuan, the company said on its WeChat account.
StairMed said it was the first company in the implantable BCI field to receive investments from both Alibaba, which owns the South China Morning Post, and Tencent Holdings.
Alibaba and Tencent “have deep strengths in multimodal large models, computing infrastructure, smart hardware and ecosystem deployment, which can be deeply integrated with StairMed’s globally leading brain-computer interface hardware and clinical translation experience”, founder Li Xue said in a statement.
The start-up, founded in 2021 by Li and fellow scientist Zhao Zhengtuo, develops tiny brain implants capable of reading and transmitting neural signals at high speed, as well as ultra-thin flexible electrodes and the robotic tools required to insert them. Zhao completed his postdoctoral research at Rice University after studying at the University of Texas at Austin.
The company plans to launch a “large-scale” clinical trial in mid-2026, aiming to enrol and implant about 40 patients by the end of the year. “By late 2026, StairMed’s total number of clinical implants is expected to approach, or even surpass, the 21 cases reported in trials by Elon Musk’s Neuralink,” the statement said.
It completed three BCI clinical trial implants last year.
StairMed, which uses technology similar to Neuralink, said its brain implants outperformed Elon Musk’s Neuralink in certain areas. Its implantation surgery requires drilling just a 3mm to 5mm hole in the skull, making it the least invasive among its peers. Its ultra-flexible neural electrodes are a fifth the size of Neuralink’s electrodes and hundreds of times softer, reducing the risk of brain tissue damage.
Other investors in the latest round of funding included state-backed SDIC Fund Management and Shanghai Guotou Leading Fund, as well as Shanghai-based private equity firm Yuanlai Capital, US investment firm OrbiMed, Oriza Seed, Qiming Venture Partners, Lilly Asia Ventures and Beijing-based venture capital firm Source Code Capital.
China has vowed to develop “two or three” global players in the sector by 2030 to compete with Neuralink. In a document released last year, the government set a goal of achieving breakthroughs in key BCI technologies by 2027, with plans including establishing an advanced technology system and an industrial framework.


China’s biotech firms move up value chain as drug deals evolve beyond licensing: analysts

Expect ‘high tide’ of Chinese biotech deals as threat of US curbs fades: analysts

Alibaba open-sources medical AI model that can detect cancer and nearly 150 conditions

How China plans to ‘firmly rank at the global forefront’ with 25% of first-in-class drugs

Biomedicine: Companies

In a first for China, Neuracle’s implantable brain-computer interface wins approval

A man demonstrates a robotic hand with a brain-computer interface at the China International Import Expo on November 7, 2025.  Neuracle’s regulatory milestone underscores China’s accelerating push in neurotechnology. Photo: AFP

Start-up StairMed has raised more than US$70 million in its latest funding round. Photo: QQ.com

China investors energise Hong Kong biotech stocks. Is foreign money missing out?

Overseas capital tends to cherry-pick a few big-cap pharmaceutical companies rather than buy the biotech sector broadly, according to an analyst. Photo: Handout

At least 13 healthcare companies have been added to the southbound list of the Stock Connect. Photo: Shutterstock

Insilico Medicine advances Middle East push with UAE AI drug discovery deal

The agreement was reached during the World Health Expo in Dubai between February 9 and 12, about two weeks before the United States and Israel launched military strikes on Iran. Photo: Shutterstock

China and Hong Kong should relax biotech listing rules, venture capitalist says

 Biotechnology was explicitly included as a “strategic emerging pillar industry” in China’s government work report during the “two sessions” Photo: Shutterstock 

Regulatory bottlenecks have slowed the pipeline of new listings, says a leading venture capitalist. Photo: Sun Yeung

China biotech outlicensing tops US$52 billion in first 2 months after global deal surge

The logo of Sino Biopharmaceutical is seen on a building in Beijing, April 22, 2021. Photo: VCG via Getty Images

Exterior view of the Sanofi head office in Gentilly, France, March 21, 2021. Photo: Shutterstock Images

Healthcare investors keeping an eye on ‘two sessions’ for clarity on drug pricing

Staff members dispense medicines at a pharmacy in Wuhan, in central China’s Hubei province, on February 27, 2020. Photo: Xinhua

Cancer drugs proceed through a factory in Guangzhou in China’s southern Guangdong province. Photo: Handout

Business

Banking & Finance

China Business

Companies

Money

Markets & Investing

Money News

News

China

Money & Wealth

China Future Tech

Biomedicine

Tech

Tech Trends

China’s BCI start-ups, seen as potential rivals to Elon Musk’s Neuralink, gain momentum as regulatory support and new capital fuel growth


China’s BCI start-ups, seen as potential rivals to Elon Musk’s Neuralink, gain momentum as regulatory support and new capital fuel growth.


In a first for China, Neuracle’s implantable brain-computer interface wins approval

.css-1c6uqr6{color:inherit;font-weight:inherit;font-size:inherit;font-family:inherit;line-height:inherit;overflow-wrap:break-word;}China’s BCI start-ups, seen as potential rivals to Elon Musk’s Neuralink, gain momentum as regulatory support and new capital fuel growth

China’s BCI start-ups, seen as potential rivals to Elon Musk’s Neuralink, gain momentum as regulatory support and new capital fuel growth